These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Identification of a 6-Gene Signature Associated with Resistance to Tyrosine Kinase Inhibitors: Prognosis for Clear Cell Renal Cell Carcinoma. Li Q; Yang W; Lu M; Zhang R Med Sci Monit; 2020 Dec; 26():e927078. PubMed ID: 33296352 [TBL] [Abstract][Full Text] [Related]
9. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor. Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607 [TBL] [Abstract][Full Text] [Related]
10. Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. Verbiest A; Couchy G; Job S; Zucman-Rossi J; Caruana L; Lerut E; Oyen R; de Reyniès A; Laguerre B; Rioux-Leclercq N; Wozniak A; Joniau S; Van Poppel H; Van Den Eynde K; Beuselinck B Clin Genitourin Cancer; 2018 Jun; 16(3):e605-e612. PubMed ID: 29239846 [TBL] [Abstract][Full Text] [Related]
11. Fatty acid binding protein 7 may be a marker and therapeutic targets in clear cell renal cell carcinoma. Nagao K; Shinohara N; Smit F; de Weijert M; Jannink S; Owada Y; Mulders P; Oosterwijk E; Matsuyama H BMC Cancer; 2018 Nov; 18(1):1114. PubMed ID: 30442117 [TBL] [Abstract][Full Text] [Related]
12. Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy. Verbiest A; Couchy G; Job S; Caruana L; Lerut E; Oyen R; de Reyniès A; Tosco L; Joniau S; Van Poppel H; Van Raemdonck D; Van Den Eynde K; Wozniak A; Zucman-Rossi J; Beuselinck B Eur Urol; 2018 Oct; 74(4):474-480. PubMed ID: 29463434 [TBL] [Abstract][Full Text] [Related]
13. Identification of subtype specific biomarkers of clear cell renal cell carcinoma using random forest and greedy algorithm. Wu Y; Han W; Xu D; Wang X; Yang J; Lu Z; Chen X; Ding Y Biosystems; 2021 Jun; 204():104372. PubMed ID: 33582210 [TBL] [Abstract][Full Text] [Related]
14. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759 [TBL] [Abstract][Full Text] [Related]
16. Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy. Park JY; Lee JL; Baek S; Eo SH; Go H; Ro JY; Cho YM Hum Pathol; 2014 Jul; 45(7):1437-44. PubMed ID: 24784922 [TBL] [Abstract][Full Text] [Related]
17. Clinical utility of the S3-score for molecular prediction of outcome in non-metastatic and metastatic clear cell renal cell carcinoma. Büttner F; Winter S; Rausch S; Hennenlotter J; Kruck S; Stenzl A; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M; Schaeffeler E BMC Med; 2018 Jul; 16(1):108. PubMed ID: 29973214 [TBL] [Abstract][Full Text] [Related]
18. FOXC2 and CLIP4 : a potential biomarker for synchronous metastasis of ≤7-cm clear cell renal cell carcinomas. Ahn J; Han KS; Heo JH; Bang D; Kang YH; Jin HA; Hong SJ; Lee JH; Ham WS Oncotarget; 2016 Aug; 7(32):51423-51434. PubMed ID: 27283491 [TBL] [Abstract][Full Text] [Related]